BNTX three-lens brief
Evidence-based stock research on BNTX. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Underperforming SPY by 10.5pp over 30 days.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 10.5pp over 30 days.
- P/E of 161 — priced for high growth; little margin of safety.
- Analyst mean target $112.89 — 29% above current (20 analysts).
- Negative free cash flow last quarterly (-$1.59B).
BNTX closed at $87.65 (+0.50%) as of 2026-11-12. Market cap: $21.73B. P/E (trailing) 160.8. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $112.89 — 29% above current (20 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.; underperforming SPY by 10.5pp over 30 days.. Last quarter: Revenue $1.29B, net income $184.50M, free cash flow -$1.59B.
Why three lenses on BNTX, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BNTX across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/BNTX" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BNTX brief"></iframe>